| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6176 |
Provisional Schedule
| Expected publication | 26 June 2024 |
Project Team
| Project lead | Celia Mayers |
Email enquiries
- If you have any queries please email TATeam6@nice.org.uk
| External Assessment Group | Liverpool Reviews and Implementation Group, University of Liverpool |
Stakeholders
| Companies sponsors | Novartis Pharmaceuticals (iptacopan) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | PNH Support |
| Professional groups | National PNH Service |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Comparator companies | Alexion Pharmaceuticals (danicopan eculizumab, ravulizumab) |
| Swedish Orphan Biovitrum (pegcetacoplan) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 April 2024 | Committee meeting |
| 22 August 2023 | Invitation to participate |
| 24 May 2023 - 22 June 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6176 |
| 24 May 2023 | In progress. Scoping commencing |
| 09 September 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our interim process and methods, please see our health technology evaluations: interim methods and process guide for the proportionate approach to technology appraisals